NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results